FindTrial
Sign In

Open label, efficacy and safety study of long-term 6-methylsulfinylhexyl Isothiocyanate(6-MSITC) administration to Duchenne muscular dystrophy

Open label, efficacy and safety study of long-term 6-methylsulfinylhexyl Isothiocyanate(6-MSITC) administration to Duchenne muscular dystrophy - Long-term 6-MSITC administration to Duchenne muscular dystrophy

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000033016
Enrollment
3
Registered
2018-08-01
Start date
2018-08-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Duchenne muscular dystrophy

Interventions

6-methylsulfinylhexyl Isothiocyanate
6-MSITC Oral administraion, 3 times a day 9mg/day for 8 weeks

Sponsors

Kobe University
Lead Sponsor
The Faculty of Rehabilitation, Kobe Gakuin University Laboratory of Molecular Life Science, Foundation for Biomedical Research and Innovation
Collaborator

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: A patient with Duchenne muscular dystrophy confirmed by genetic test and/or immunohistological findings in muscle biopsy DMD patient who is taking a steroid therapy with consistent dose.

Exclusion criteria

Exclusion criteria: DMD patient who has a severe complication DMD patient who joined other clinical trials within 6 months DMD patient who cannot swallow a capsule

Design outcomes

Primary

MeasureTime frame
Urinary titin concentration—

Secondary

MeasureTime frame
Serum CK level, Urinary 8OhDG Serum AST,ALT,BUN and Cr WBC,Hb,Plt Urinary NAG, Urinary beta2MG and Urinary Protein to Cr ratio.—

Countries

Japan

Contacts

Public ContactHiroyuki Awano

Kobe University Graduate School of Medicine Department of Pediatrics

awahiro@med.kobe-u.ac.jp+81-78-382-6090

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026